Month: February 2024

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid...

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C....

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in...

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...

error: Content is protected !!